Survodutide is an investigational once-weekly subcutaneous GLP-1/glucagon dual agonist being developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials showed about 19 percent weight loss at 46 weeks and roughly 83 percent histologic MASH response at the high dose. Phase 3 trials are ongoing, with FDA submission expected in 2026 or 2027. It is not currently approved.
What Survodutide Is
Survodutide (development code BI 456906) is a synthetic peptide engineered to activate two receptors:
- GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin release
- Glucagon receptor — increased energy expenditure, hepatic fat oxidation, lipolysis
It is administered once weekly by subcutaneous injection with a gradual titration to limit gastrointestinal side effects. The balance between GLP-1 and glucagon activity is engineered so the GLP-1 glucose-lowering effects offset glucagon’s glucose-raising tendency, while preserving glucagon’s metabolic-rate and liver-fat advantages.
Mechanism: The Glucagon Question
Glucagon raises blood glucose by mobilizing hepatic glucose output — that’s why it’s used as rescue therapy for severe hypoglycemia. So why include glucagon receptor activation in a diabetes/obesity drug?
Because glucagon also:
- Increases basal metabolic rate by 10 to 20 percent acutely
- Promotes hepatic fat oxidation and decreases liver fat content
- Stimulates lipolysis in adipose tissue
- Reduces food intake centrally
The trick is dosing it alongside enough GLP-1 activity to keep glucose in check. Survodutide is calibrated for that balance, and Phase 2 data have not shown adverse glycemic signals in non-diabetic populations.
Phase 2 Obesity Trial
The Phase 2 obesity trial (le Roux et al., Lancet Diabetes Endocrinol 2024) enrolled 387 adults with overweight or obesity (no diabetes) and randomized them to survodutide 0.6, 2.4, 3.6, 4.8 mg weekly or placebo for 46 weeks.
| Dose | Mean weight loss | Achieving ≥10% loss |
|---|---|---|
| Placebo | ~2.0% | ~9% |
| 0.6 mg | ~6.2% | ~30% |
| 2.4 mg | ~12.5% | ~57% |
| 3.6 mg | ~13.2% | ~63% |
| 4.8 mg | ~18.7% | ~80% |
Phase 2 MASH Trial
A separate Phase 2 trial (Sanyal et al., NEJM 2024) studied survodutide in adults with biopsy-confirmed MASH and fibrosis F1-F3.
- Approximately 83 percent of participants on the highest dose achieved a histologic MASH response at 48 weeks versus 18 percent on placebo
- Liver fat reduction was substantial — often greater than 70 percent
- Fibrosis improvement was modest but present
This is one of the strongest histologic MASH signals reported for any drug, although Phase 3 confirmation is still required.
How Survodutide Compares
| Drug | Mechanism | Phase 2/3 weight loss | MASH effect | Status (2026) |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | Modest steatosis reduction | FDA approved (T2D, obesity) |
| Tirzepatide | GLP-1 + GIP | ~21% | Significant MASH effect | FDA approved (T2D, obesity) |
| Survodutide | GLP-1 + glucagon | ~19% (Phase 2) | ~83% histologic response (Phase 2) | Investigational |
| Retatrutide | GLP-1 + GIP + glucagon | ~24% (Phase 2) | Strong liver fat reduction | Investigational |
| Resmetirom (Rezdiffra) | Thyroid receptor-β | None expected | ~26% MASH response | FDA approved (MASH) |
The MASH numbers in particular suggest survodutide could position itself as both a weight-loss and liver-disease therapy.
Side Effects
- Nausea — most common, especially during dose escalation
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Mild heart-rate increase
- Injection site reactions
- Theoretical class risks: pancreatitis, gallbladder events
- Glucagon-related monitoring: glucose excursions, hepatic effects (so far not clinically problematic)
Discontinuation for GI side effects was higher at the top dose (about 24 percent in the obesity trial), suggesting the titration schedule needs to be gradual.
Phase 3 Program
Phase 3 trials are running in:
- Obesity (multiple populations)
- MASH with significant fibrosis (biopsy-driven)
- Type 2 diabetes glycemic outcomes
- Cardiovascular outcomes (planned)
Top-line obesity Phase 3 readouts are expected in 2025-2026 with FDA submission in 2026 or 2027.
Who Might Be a Candidate If Approved
- Adults with obesity, particularly with concomitant metabolic-associated liver disease
- Adults with biopsy-confirmed MASH and fibrosis
- Adults with type 2 diabetes pursuing weight loss
- Patients in whom existing GLP-1s have not produced enough weight loss
Where It Fits Among Emerging Therapies
Survodutide is one of three glucagon-containing incretin drugs in late development, alongside retatrutide. Oral options are advancing with orforglipron and combinations like CagriSema are filing for approval. For broader context, see our overview of treatment, diet and nutrition, and complications and related conditions including liver disease.
Open Questions
- Long-term durability of weight loss past 1 year
- Confirmation of MASH effect in Phase 3 with histologic endpoints
- Cardiovascular outcomes
- Whether glucagon activation has any subgroup-specific safety considerations
- Effects on kidney function, bone density, and lean mass
What to Discuss with a Clinician
- Personal history of liver disease and recent imaging or FibroScan results
- Whether existing approved options have been tried for weight or glucose
- Pancreatitis, gallbladder, and cardiovascular history
- Interest in clinical trial participation while commercial supply is unavailable
- Diet, exercise, and alcohol patterns alongside any liver-directed therapy
The Bottom Line
Survodutide is an investigational once-weekly GLP-1/glucagon dual agonist that produced about 19 percent weight loss in Phase 2 obesity trials and a striking ~83 percent histologic MASH response in a Phase 2 liver trial — among the strongest liver effects reported for any agent. It is not FDA approved as of 2026. Phase 3 trials are ongoing with submission anticipated in 2026 or 2027. Side effects are class-typical with mostly gastrointestinal issues during titration. Talk to your clinician about approved options or clinical trial participation if weight loss and liver disease are dual concerns.
